1-9 of 9
Neil D. Palmisiano
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Initial Results of a Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Gina Keiffer, Lindsay Wilde, Chetan Jeurkar, Margaret Kasner, Neil D. Palmisiano
Journal: Blood
Blood (2024) 144 (Supplement 1): 6719.
https://doi.org/10.1182/blood-2024-210067
Published: 2024
Journal Articles

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Amer M. Zeidan, Eunice S. Wang, Ghayas C. Issa, Harry Erba, Jessica Kaplan Altman, Suresh Kumar Balasubramanian, Stephen Anthony Strickland, Gail J. Roboz, Gary J. Schiller, Christine M. McMahon, Neil D. Palmisiano, Yazan F. Madanat, Marcello Rotta, Kalyan Nadiminti, Helen Wei, Marcie Riches, Daniel Corum, Mollie Leoni, Stephen Dale, Amir T. Fathi
Journal: Blood
Blood (2024) 144 (Supplement 1): 214.
https://doi.org/10.1182/blood-2024-198218
Published: 2024
Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Joshua F Zeidner, Junichiro Yuda, Justin M. Watts, Mark J. Levis, Harry P. Erba, Kentaro Fukushima, Takahiro Shima, Neil D. Palmisiano, Eunice S. Wang, Uma Borate, Joseph Brandwein, Cristina Papayannidis, Pau Montesinos, Gina Keiffer, Yasushi Miyazaki, Naoko Hosono, Takayuki Ikezoe, Yoshiaki Ogawa, Timothy S Pardee, Stephen Anthony Strickland, Koichi Onodera, Shang-Ju Wu, Melissa G Ooi, Emmanuel Raffoux, Susana Vives, Alireza Eghtedar, Hongliang Cai, Curtis Allred, Bo Xu, Priya Robson, Akinobu Watanabe, Matthew Hitron, Jatin Shah, Hagop M. Kantarjian, Naval Daver
Journal: Blood
Blood (2024) 144 (Supplement 1): 213.
https://doi.org/10.1182/blood-2024-194827
Published: 2024
Journal Articles

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1 -m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Amir T. Fathi, Ghayas C. Issa, Eunice S. Wang, Harry Erba, Jessica Kaplan Altman, Suresh Kumar Balasubramanian, Gail J. Roboz, Gary J. Schiller, Christine M. McMahon, Neil D. Palmisiano, Mark B Juckett, Yazan F. Madanat, Marcello Rotta, Keith W. Pratz, George Yaghmour, Kalyan Nadiminti, Helen Wei, Marcie Riches, Daniel Corum, Mollie Leoni, Stephen Dale, Amer M. Zeidan
Journal: Blood
Blood (2024) 144 (Supplement 1): 2880.
https://doi.org/10.1182/blood-2024-199170
Published: 2024
Journal Articles

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Kashish J. Shah, Mobachir El Kettani, Ravi Narra, Alice Mims, Alexander Coltoff, Georgio Medawar, Brooke Hisrich, Rory M. Shallis, Cameron J. Hunter, Vamsi K. Kota, Tamer Othman, Brian A. Jonas, Shreya Desai, Guilherme Sacchi de Camargo Correia, Anand Ashwin Patel, Adam S. Duvall, Neil D. Palmisiano, Emily K Curran, Zulfa Omer, Anjali S. Advani, Ehab L. Atallah, Mark R. Litzow, Talha Badar
Journal: Blood
Blood (2024) 144 (Supplement 1): 4184.
https://doi.org/10.1182/blood-2024-205812
Published: 2024
Journal Articles

Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)

Catherine S. Diefenbach, MD, Fangxin Hong, PhD, Kevin A David, MD, Jonathon Cohen, Michael Robertson, MD, Ranjana Advani, MD, Neil D. Palmisiano, MD, Richard F. Ambinder, MD PhD, Brad S Kahl, Stephen Ansell, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1106.
https://doi.org/10.1182/blood.V128.22.1106.1106
Published: 2016
Journal Articles

Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

Barbara Marie Galligan, MD, Denice Tsao-Wei, Susan Groshen, Mark Kirschabum, Robert O'Donnell, Paul R. Kaesberg, MD, Tanya Siddiqui, Leslie Popplewell, Ailawadhi Sikander, Htut Myo, Robert Chen, John F. DiPersio, MD PhD, Neil D. Palmisiano, MD, David F. Claxton, MD, Edward M. Newman, PhD, Joseph Tuscano, MD
Journal: Blood
Blood (2015) 126 (23): 3977.
https://doi.org/10.1182/blood.V126.23.3977.3977
Published: 2015
Journal Articles

Clinical Outcomes of 2-Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Effects of CD34 Stem Cell Dose in the Setting of a Consistent T-Cell Dose

Sameh Gaballa, MD, Neil D. Palmisiano, MD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Margaret Kasner, MD, Ubaldo Martinez, MD, John L. Wagner, MD, Mark Weiss, MD, Neal Flomenberg, MD, Dolores Grosso, DNP
Journal: Blood
Blood (2014) 124 (21): 1212.
https://doi.org/10.1182/blood.V124.21.1212.1212
Published: 2014
Journal Articles

The Addition Of Bortezomib (Velcade®) To The Combination Of Mitoxantrone and Etoposide For Relapsed Or Refractory Acute Leukemia Does Not Appear To Improve The Likelihood Of Response: Results Of a Phase II Trial

Neil D. Palmisiano, MD, Sameh Gaballa, MD, Bijoyesh Mookerjee, MD, John L. Wagner, MD, Margaret Kasner, MD, Matthew Carabasi, MD, Onder Alpdogan, MD, Ubaldo Martinez, MD, Mark Weiss, MD, Neal Flomenberg, MD, Joanne Filicko-O'Hara, MD
Journal: Blood
Blood (2013) 122 (21): 2689.
https://doi.org/10.1182/blood.V122.21.2689.2689
Published: 2013